Garcia-Reitboeck, P;
Phillips, A;
Piers, TM;
Villegas-Llerena, C;
Butler, M;
Mallach, A;
Rodrigues, C;
... Pocock, JM; + view all
(2018)
Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis.
Cell Reports
, 24
(9)
pp. 2300-2311.
10.1016/j.celrep.2018.07.094.
Preview |
Text (Published article)
1-s2.0-S2211124718312270-main.pdf - Published Version Download (3MB) | Preview |
Preview |
Text (Supplementary file)
Garcia_Reitboeck_1-s2.0-S2211124718312270-mmc1.pdf Download (1MB) | Preview |
Abstract
Dysfunction of microglia, the brain’s immune cells, is linked to neurodegeneration. Homozygous missense mutations in TREM2 cause Nasu-Hakola disease (NHD), an early-onset dementia. To study the consequences of these TREM2 variants, we generated induced pluripotent stem cell-derived microglia-like cells (iPSC-MGLCs) from patients with NHD caused by homozygous T66M or W50C missense mutations. iPSC-MGLCs expressed microglial markers and secreted higher levels of TREM2 than primary macrophages. TREM2 expression and secretion were reduced in variant lines. LPS-mediated cytokine secretion was comparable between control and TREM2 variant iPSC-MGLCs, whereas survival was markedly reduced in cells harboring missense mutations when compared with controls. Furthermore, TREM2 missense mutations caused a marked impairment in the phagocytosis of apoptotic bodies, but not in Escherichia coli or zymosan substrates. Coupled with changes in apoptotic cell-induced cytokine release and migration, these data identify specific deficits in the ability of iPSC-MGLCs harboring TREM2 missense mutations to respond to specific pathogenic signals.
Archive Staff Only
 |
View Item |
